Insights EmergeEmerging companies and life sciences news

Biotech & Pharma · Week of Nov 9, 2026

Eli Lilly, Tango, Immunic set out data and Q3 updates: biotech week

Immunic, Tango, PDS Biotech, Aardvark and Compugen posted Q3 losses and set 2027 milestones, while Protalix and Castle took data to November meetings.

· Insights Emerge newsroom

Five of this week's eight releases were third-quarter 2026 reports from clinical-stage companies, and most centred on cash runway and the next readout. Immunic says top-line Phase 3 ENSURE data in relapsing MS are due in December 2026. Tango Therapeutics, Compugen and Aardvark Therapeutics each pointed to 2027 events: a pivotal Phase 3 start, an ovarian cancer readout and an FDA meeting, respectively. Balance sheets varied widely. Tango reported $977.5 million in cash, cash equivalents and marketable securities. PDS Biotech reported $15.2 million and completed the initial closing of a PIPE of up to $22.3 million led by Nant Capital, LLC.

The rest of the week was conference data. Eli Lilly and Company outlined ObesityWeek 2026 presentations across Zepbound, Foundayo, EloraTZP and retatrutide, including outcomes beyond weight loss such as sleep apnea and knee osteoarthritis pain. Protalix BioTherapeutics brought Phase 1 PRX-115 gout data to ACR Convergence 2026, and Castle Biosciences presented DecisionDx-Melanoma risk-stratification analyses at two dermatology meetings.

  1. Eli Lilly and Company

    Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

    Eli Lilly and Company says it will present data at ObesityWeek 2026 (November 14 to 17), including a Phase 2 result in which EloraTZP produced weight loss of up to an average of 23.3% at 48 weeks and retatrutide data from TRIUMPH-1 showing apnea-hypopnea index reductions of up to 60.6% at 80 weeks. The presentations extend Lilly's obesity portfolio data into sleep apnea, knee osteoarthritis pain and adolescent obesity.

  2. Immunic, Inc.

    Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

    Immunic reported a third-quarter net loss of approximately $42.3 million and $132.0 million in cash, which it expects to fund operations into late 2027. The company says top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS are expected in December 2026, with a planned US NDA in mid-2027 if results are positive.

  3. Tango Therapeutics, Inc.

    Tango Therapeutics Reports Third Quarter 2026 Financial Results

    Tango Therapeutics reported a third-quarter net loss of $68.4 million against net income of $15.9 million a year earlier, after collaboration revenue fell to $0 following the end of Gilead research activities. The company plans to start a pivotal Phase 3 study of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer in the first half of 2027, citing an 82% objective response rate reported at ESMO in later-line patients.

  4. PDS Biotechnology Corp

    PDS Biotech Reports Third Quarter 2026 Financial Results

    PDS Biotechnology reported a third-quarter net loss of $7.6 million and cash of $15.2 million, and completed the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC. A contingent milestone closing is tied to submitting a registrational Phase 3 protocol for PDS0301 to the FDA, and Nant Capital designees including Dr. Patrick Soon-Shiong were appointed to the board.

  5. Aardvark Therapeutics, Inc.

    Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

    Aardvark Therapeutics says the FDA lifted the clinical hold on ARD-101 for hyperphagia in Prader-Willi Syndrome in October 2026 and agreed to an open-label trial at 200 mg BID. An FDA meeting is scheduled for the first quarter of 2027; the company reported a $19.2 million quarterly net loss and $60.3 million in cash and investments.

  6. Compugen Ltd.

    Compugen Reports Third Quarter 2026 Results

    Compugen reported third-quarter revenues of approximately $3.8 million and a net loss of approximately $5.8 million, and says its MAIA-ovarian trial of COM701 is fully enrolled with 62 patients and results are expected by the end of the first quarter of 2027. The company says Phase 3 results for AstraZeneca's rilvegostomig in ARTEMIDE-Biliary01 are now anticipated in the second half of 2027, and that its cash of approximately $117.5 million funds operations into 2029.

  7. Protalix BioTherapeutics, Inc.

    Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

    Protalix BioTherapeutics is presenting Phase 1 data at ACR Convergence 2026 showing that at 36 mg, mean plasma uric acid stayed below the 6.0 mg/dL target for up to 12 weeks after a single PRX-115 infusion. The company reported one anaphylactic reaction that resolved and expects top-line Phase 2 RELEASE results in the second half of 2027.

  8. Castle Biosciences, Inc.

    DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

    Castle Biosciences is presenting DecisionDx-Melanoma data at SDPA and Dermato-Onco2026. One study of 1,726 stage I–III patients showed five-year recurrence-free survival of 92.5% for low-risk i31-ROR results versus 54.2% for high-risk results. The company says the algorithm predicted five-year recurrence more accurately than AJCC staging.

This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Insights Emerge reporting.